Lilly Drug Patent Portfolio
Lilly owns 20 orange book drugs protected by 55 US patents with Humulin 70/30 having the least patent protection, holding only 1 patent. And Evista with maximum patent protection, holding 13 patents. Given below is the list of Lilly's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7517334 | Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose | 25 Mar, 2025 | Expired |
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage | 09 Aug, 2024 | Expired |
| US7772209 | Antifolate combination therapies | 24 May, 2022 | Expired |
| US7772209 | Antifolate combination therapies | 24 Nov, 2021 | Expired |
| US6821975 | Beta-carboline drug products | 19 May, 2021 | Expired |
| US6821975 | Beta-carboline drug products | 19 Nov, 2020 | Expired |
| US6943166 | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction | 26 Oct, 2020 | Expired |
| US7182958 | β-carboline pharmaceutical compositions | 26 Oct, 2020 | Expired |
| US6943166 | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction | 26 Apr, 2020 | Expired |
| US7182958 | β-carboline pharmaceutical compositions | 26 Apr, 2020 | Expired |
| US6596756 | Treatment of fibromyalgia | 10 Mar, 2020 | Expired |
| US6596756 | Treatment of fibromyalgia | 10 Sep, 2019 | Expired |
| US6977077 | Method of increasing bone toughness and stiffness and reducing fractures | 19 Aug, 2019 | Expired |
| US7163684 | Method of increasing bone toughness and stiffness and reducing fractures | 19 Aug, 2019 | Expired |
| US7351414 | Method of reducing the risk of bone fracture | 19 Aug, 2019 | Expired |
| US6770623 | Stabilized teriparatide solutions | 08 Dec, 2018 | Expired |
| US7144861 | Stabilized teriparatide solutions | 08 Dec, 2018 | Expired |
| US7550434 | Stabilized teriparatide solutions | 08 Dec, 2018 | Expired |
| US5859006 | Tetracyclic derivatives; process of preparation and use | 21 May, 2018 | Expired |
| US5910319 | Fluoxetine enteric pellets and methods for their preparation and use | 29 Nov, 2017 | Expired |
| US5985322 | Method for the treatment of CNS disorders | 29 Nov, 2017 | Expired |
| US5859006 | Tetracyclic derivatives; process of preparation and use | 21 Nov, 2017 | Expired |
| US6960577 | Combination therapy for treatment of refractory depression | 01 Nov, 2017 | Expired |
| US5910319 | Fluoxetine enteric pellets and methods for their preparation and use | 29 May, 2017 | Expired |
| US5985322 | Method for the treatment of CNS disorders | 29 May, 2017 | Expired |
| USRE39030 | Fluoxetine enteric pellets and methods for their preparation and use | 29 May, 2017 | Expired |
| US5658590 | Treatment of attention-deficit/hyperactivity disorder | 26 May, 2017 | Expired |
| US5945416 | Method for treating pain | 24 Mar, 2017 | Expired |
| US6458811 | Benzothiophenes formulations containing same and methods | 10 Mar, 2017 | Expired |
| US6797719 | Benzothiophenes, formulations containing same, and methods | 10 Mar, 2017 | Expired |
| US6894064 | Benzothiophenes, formulations containing same, and methods | 10 Mar, 2017 | Expired |
| US8030330 | Benzothiophenes, formulations containing same, and methods | 10 Mar, 2017 | Expired |
| US5344932 | N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives | 24 Jan, 2017 | Expired |
| US5658590 | Treatment of attention-deficit/hyperactivity disorder | 26 Nov, 2016 | Expired |
| US5344932 | N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives | 24 Jul, 2016 | Expired |
| US6140329 | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence | 11 Jul, 2016 | Expired |
| US5508276 | Duloxetine enteric pellets | 18 Jan, 2015 | Expired |
| US5508276 | Duloxetine enteric pellets | 18 Jul, 2014 | Expired |
| US5474978 | Insulin analog formulations | 16 Jun, 2014 | Expired |
| US5461031 | Monomeric insulin analog formulations | 16 Jun, 2014 | Expired |
| US5747642 | Monomeric insulin analog formulations | 16 Jun, 2014 | Expired |
| US5478847 | Methods of use for inhibiting bone loss and lowering serum cholesterol | 02 Mar, 2014 | Expired |
| US5811120 | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation | 02 Mar, 2014 | Expired |
| US5972383 | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation | 02 Mar, 2014 | Expired |
| USRE39050 | Methods of use for inhibiting bone loss and lowering serum cholesterol | 02 Mar, 2014 | Expired |
| US5023269 | 3-aryloxy-3-substituted propanamines | 11 Dec, 2013 | Expired |
| US5023269 | 3-aryloxy-3-substituted propanamines | 11 Jun, 2013 | Expired |
| US5464826 | Method of treating tumors in mammals with 2',2'-difluoronucleosides | 07 May, 2013 | Expired |
| US5514646 | Insulin analogs modified at position 29 of the B chain | 07 May, 2013 | Expired |
| US5464826 | Method of treating tumors in mammals with 2',2'-difluoronucleosides | 07 Nov, 2012 | Expired |
| US5393763 | Methods for inhibiting bone loss | 28 Jul, 2012 | Expired |
| US5457117 | Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride | 28 Jul, 2012 | Expired |
| US6906086 | Methods for inhibiting bone loss | 28 Jul, 2012 | Expired |
| USRE38968 | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride | 28 Jul, 2012 | Expired |
| USRE39049 | Methods for inhibiting bone loss | 28 Jul, 2012 | Expired |
Latest Legal Activities on Lilly's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Lilly.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 12 Sep, 2022 | US7772209 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 28 Mar, 2022 | US7772209 (Litigated) |
|
Expire Patent
Critical
| 26 Jul, 2021 | US7550434 |
|
Maintenance Fee Reminder Mailed
Critical
| 08 Feb, 2021 | US7550434 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Sep, 2020 | US7517334 |
|
Expire Patent
Critical
| 04 May, 2020 | US7351414 |
|
Maintenance Fee Reminder Mailed
Critical
| 18 Nov, 2019 | US7351414 |
|
Expire Patent
Critical
| 11 Nov, 2019 | US8030330 |
| Review Certificate Mailed | 26 Sep, 2019 | US7772209 (Litigated) |
| Review Certificate | 06 Sep, 2019 | US7772209 (Litigated) |
| Review Certificate Mailed | 27 Jun, 2019 | US6821975 (Litigated) |
| Review Certificate Mailed | 26 Jun, 2019 | US7182958 (Litigated) |
| Review Certificate | 12 Jun, 2019 | US6821975 (Litigated) |
| Review Certificate | 12 Jun, 2019 | US7182958 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 27 May, 2019 | US8030330 |
Lilly's Drug Patent Litigations
Lilly's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 14, 2013, against patent number US7772209. The petitioner Accord Healthcare, Inc., USA, challenged the validity of this patent, with Eli Lilly and Company as the respondent. Click below to track the latest information on how companies are challenging Lilly's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6943166 | June, 2018 |
Terminated-Denied
(07 Dec, 2018)
| ICOS Corporation | Aquestive Therapeutics, Inc. |
| US6943166 | July, 2017 |
Terminated-Settled
(27 Oct, 2017)
| ICOS Corporation | Dr. Reddy's Laboratories, Inc. |
| US7772209 | November, 2015 |
FWD Entered
(05 Oct, 2017)
| Eli Lilly and Company | Neptune Generics, LLC |
| US7772209 | December, 2015 |
FWD Entered
(05 Oct, 2017)
| Eli Lilly and Company | Sandoz Inc. |
| US7772209 | June, 2016 |
FWD Entered
(05 Oct, 2017)
| Eli Lilly and Company | Wockhardt Bio AG |
| US7772209 | July, 2016 |
FWD Entered
(05 Oct, 2017)
| Eli Lilly and Company | Apotex Inc. |
| US7772209 | July, 2016 |
FWD Entered
(05 Oct, 2017)
| Eli Lilly and Company | Teva Pharmaceuticals USA, Inc. |
| US7772209 | July, 2016 |
FWD Entered
(05 Oct, 2017)
| Eli Lilly and Company | Wockhardt Bio AG |
| US7772209 | July, 2016 |
FWD Entered
(05 Oct, 2017)
| Eli Lilly and Company | Apotex Inc. |
| US6943166 | July, 2017 |
Terminated-Settled
(03 Oct, 2017)
| ICOS Corporation | Argentum Pharmaceuticals LLC |
| US6943166 | November, 2016 |
Terminated-Settled
(16 Aug, 2017)
| ICOS Corporation | Mylan Pharmaceuticals Inc. |
| US6943166 | December, 2016 |
Terminated-Denied
(03 Jul, 2017)
| ICOS Corporation | MonoSol Rx, LLC |
| US6943166 | February, 2016 |
Terminated-Denied
(01 Sep, 2016)
| ICOS Corporation | IntelGenx Corp. |
| US6821975 | January, 2015 |
FWD Entered
(03 Aug, 2016)
| ICOS Corporation | Actelion Pharmaceuticals Ltd |
| US7182958 | January, 2015 |
FWD Entered
(03 Aug, 2016)
| ICOS Corporation | Actelion Pharmaceuticals Ltd |
| US7772209 | June, 2013 |
Terminated-Denied
(01 Oct, 2013)
| Eli Lilly and Company | Accord Healthcare, Inc., USA |
Lilly Drug Patents' Oppositions Filed in EPO
Lilly drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 17, 2008, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP01948214A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP01948214A | Oct, 2012 | Actavis Deutschland GmbH & Co. KG | Opposition rejected |
| EP01948214A | Jan, 2008 | Teva Pharmaceutical Industries Ltd. | Opposition rejected |
Lilly's Family Patents
Lilly Drug List
Given below is the complete list of Lilly's drugs and the patents protecting them.
1. Alimta
Alimta is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7772209
(Pediatric)
| Antifolate combination therapies |
24 May, 2022
(2 years ago)
| Expired |
| US7772209 | Antifolate combination therapies |
24 Nov, 2021
(3 years ago)
| Expired |
| US5344932
(Pediatric)
| N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives |
24 Jan, 2017
(8 years ago)
| Expired |
| US5344932 | N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives |
24 Jul, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alimta's drug page
2. Cialis
Cialis is protected by 9 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6821975
(Pediatric)
| Beta-carboline drug products |
19 May, 2021
(3 years ago)
| Expired |
| US6821975 | Beta-carboline drug products |
19 Nov, 2020
(4 years ago)
| Expired |
| US6943166
(Pediatric)
| Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
26 Oct, 2020
(4 years ago)
| Expired |
| US7182958
(Pediatric)
| β-carboline pharmaceutical compositions |
26 Oct, 2020
(4 years ago)
| Expired |
| US6943166 | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
26 Apr, 2020
(5 years ago)
| Expired |
| US7182958 | β-carboline pharmaceutical compositions |
26 Apr, 2020
(5 years ago)
| Expired |
| US5859006
(Pediatric)
| Tetracyclic derivatives; process of preparation and use |
21 May, 2018
(6 years ago)
| Expired |
| US5859006 | Tetracyclic derivatives; process of preparation and use |
21 Nov, 2017
(7 years ago)
| Expired |
| US6140329 | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence |
11 Jul, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cialis's drug page
3. Cymbalta
Cymbalta is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6596756
(Pediatric)
| Treatment of fibromyalgia |
10 Mar, 2020
(5 years ago)
| Expired |
| US6596756 | Treatment of fibromyalgia |
10 Sep, 2019
(5 years ago)
| Expired |
| US5508276
(Pediatric)
| Duloxetine enteric pellets |
18 Jan, 2015
(10 years ago)
| Expired |
| US5508276 | Duloxetine enteric pellets |
18 Jul, 2014
(10 years ago)
| Expired |
| US5023269
(Pediatric)
| 3-aryloxy-3-substituted propanamines |
11 Dec, 2013
(11 years ago)
| Expired |
| US5023269 | 3-aryloxy-3-substituted propanamines |
11 Jun, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cymbalta's drug page
4. Evista
Evista is protected by 13 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6458811 | Benzothiophenes formulations containing same and methods |
10 Mar, 2017
(8 years ago)
| Expired |
| US6797719 | Benzothiophenes, formulations containing same, and methods |
10 Mar, 2017
(8 years ago)
| Expired |
| US6894064 | Benzothiophenes, formulations containing same, and methods |
10 Mar, 2017
(8 years ago)
| Expired |
| US8030330 | Benzothiophenes, formulations containing same, and methods |
10 Mar, 2017
(8 years ago)
| Expired |
| US5478847 | Methods of use for inhibiting bone loss and lowering serum cholesterol |
02 Mar, 2014
(11 years ago)
| Expired |
| US5811120 | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
02 Mar, 2014
(11 years ago)
| Expired |
| US5972383 | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
02 Mar, 2014
(11 years ago)
| Expired |
| USRE39050 | Methods of use for inhibiting bone loss and lowering serum cholesterol |
02 Mar, 2014
(11 years ago)
| Expired |
| US5393763 | Methods for inhibiting bone loss |
28 Jul, 2012
(12 years ago)
| Expired |
| US5457117 | Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride |
28 Jul, 2012
(12 years ago)
| Expired |
| US6906086 | Methods for inhibiting bone loss |
28 Jul, 2012
(12 years ago)
| Expired |
| USRE38968 | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
28 Jul, 2012
(12 years ago)
| Expired |
| USRE39049 | Methods for inhibiting bone loss |
28 Jul, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evista's drug page
5. Forteo
Forteo is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7517334 | Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose |
25 Mar, 2025
(a month ago)
| Expired |
| US6977077 | Method of increasing bone toughness and stiffness and reducing fractures |
19 Aug, 2019
(5 years ago)
| Expired |
| US7163684 | Method of increasing bone toughness and stiffness and reducing fractures |
19 Aug, 2019
(5 years ago)
| Expired |
| US7351414 | Method of reducing the risk of bone fracture |
19 Aug, 2019
(5 years ago)
| Expired |
| US6770623 | Stabilized teriparatide solutions |
08 Dec, 2018
(6 years ago)
| Expired |
| US7144861 | Stabilized teriparatide solutions |
08 Dec, 2018
(6 years ago)
| Expired |
| US7550434 | Stabilized teriparatide solutions |
08 Dec, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Forteo's drug page
Explore Our Curated Drug Screens
6. Gemzar
Gemzar is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5464826
(Pediatric)
| Method of treating tumors in mammals with 2',2'-difluoronucleosides |
07 May, 2013
(12 years ago)
| Expired |
| US5464826 | Method of treating tumors in mammals with 2',2'-difluoronucleosides |
07 Nov, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gemzar's drug page
7. Humalog
Humalog is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5474978 | Insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5514646 | Insulin analogs modified at position 29 of the B chain |
07 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog's drug page
8. Humalog Kwikpen
Humalog Kwikpen is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
09 Aug, 2024
(9 months ago)
| Expired |
| US5474978 | Insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5514646 | Insulin analogs modified at position 29 of the B chain |
07 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Kwikpen's drug page
9. Humalog Mix 50/50
Humalog Mix 50/50 is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5461031 | Monomeric insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5474978 | Insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5747642 | Monomeric insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5514646 | Insulin analogs modified at position 29 of the B chain |
07 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Mix 50/50's drug page
10. Humalog Mix 50/50 Kwikpen
Humalog Mix 50/50 Kwikpen is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
09 Aug, 2024
(9 months ago)
| Expired |
| US5461031 | Monomeric insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5474978 | Insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5747642 | Monomeric insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5514646 | Insulin analogs modified at position 29 of the B chain |
07 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Mix 50/50 Kwikpen's drug page
11. Humalog Mix 75/25
Humalog Mix 75/25 is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5461031 | Monomeric insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5474978 | Insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5747642 | Monomeric insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5514646 | Insulin analogs modified at position 29 of the B chain |
07 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Mix 75/25's drug page
12. Humalog Mix 75/25 Kwikpen
Humalog Mix 75/25 Kwikpen is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
09 Aug, 2024
(9 months ago)
| Expired |
| US5461031 | Monomeric insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5474978 | Insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5747642 | Monomeric insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5514646 | Insulin analogs modified at position 29 of the B chain |
07 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Mix 75/25 Kwikpen's drug page
13. Humalog Pen
Humalog Pen is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5474978 | Insulin analog formulations |
16 Jun, 2014
(10 years ago)
| Expired |
| US5514646 | Insulin analogs modified at position 29 of the B chain |
07 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Pen's drug page
14. Humulin 70/30
Humulin 70/30 is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
09 Aug, 2024
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humulin 70/30's drug page
15. Humulin 70/30 Pen
Humulin 70/30 Pen is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
09 Aug, 2024
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humulin 70/30 Pen's drug page
16. Humulin N
Humulin N is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
09 Aug, 2024
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humulin N's drug page
17. Humulin R
Humulin R is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
09 Aug, 2024
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humulin R's drug page
18. Prozac Weekly
Prozac Weekly is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5910319
(Pediatric)
| Fluoxetine enteric pellets and methods for their preparation and use |
29 Nov, 2017
(7 years ago)
| Expired |
| US5985322
(Pediatric)
| Method for the treatment of CNS disorders |
29 Nov, 2017
(7 years ago)
| Expired |
| US5910319 | Fluoxetine enteric pellets and methods for their preparation and use |
29 May, 2017
(7 years ago)
| Expired |
| US5985322 | Method for the treatment of CNS disorders |
29 May, 2017
(7 years ago)
| Expired |
| USRE39030 | Fluoxetine enteric pellets and methods for their preparation and use |
29 May, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prozac Weekly's drug page
19. Strattera
Strattera is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5658590
(Pediatric)
| Treatment of attention-deficit/hyperactivity disorder |
26 May, 2017
(7 years ago)
| Expired |
| US5658590 | Treatment of attention-deficit/hyperactivity disorder |
26 Nov, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Strattera's drug page
20. Symbyax
Symbyax is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6960577 | Combination therapy for treatment of refractory depression |
01 Nov, 2017
(7 years ago)
| Expired |
| US5945416 | Method for treating pain |
24 Mar, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symbyax's drug page